- The shares of commercial-stage biotech Amarin Corporation ( NASDAQ: AMRN ) dropped sharply on Thursday after Stat News raised concerns over the effectiveness of its heart disease therapy Vascepa.
- Following a new analysis, the report said that multiple experts called for clinical trials to address the questions over Vascepa. Some had even urged the U.S. Food and Drug Administration (FDA) to reconsider its approval, Stat News said.
- Early this month, Amarin ( AMRN ) said it expected to receive pricing decisions for Vascepa, known as Vazkepa in Europe, in up to eight countries. The company expects to launch the product in up to six European countries this year.
For further details see:
Amarin extends losses after Stat report on cardiovascular therapy